Overview

The central theme of my research program, Pharmaceutical Outcomes and Policy Innovations (POPi), is the study of drug therapy with the goal of improving human health and quality of life.

I am particularly interested in developing models for evaluating drug effectiveness, medication use models designed to improve patient health, and effective surveillance systems to improve the safe use of medication.

I have a particular clinical interest in pediatric medicine, with specific emphases on asthma and the epidemiology and clinical management of adverse drug reactions.

Another area of interest is the translation of knowledge to aid evidence-based drug policy development. POPi contributes to solving the international drug policy crisis on two levels: the public policy level (federal and provincial), and the clinical policy level. In this way the needs of government are served to manage drug budgets, the needs of clinicians to improve patient care, and the public need to understand and improve the effectiveness, safety and cost effectiveness of drugs.

Publications

Further investigation of the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research
Drögemöller BI, Brooks B, Monzon JG, Wright GE, Liu G, Renouf DJ, Kollmannsberger C, Bedard PL, Hayden MR, Gelmon KA, Carleton B, Ross CJ
DOI: 10.1158/1078-0432.ccr-17-2810
PubMed: 29358504
01/2018

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
Pediatric blood & cancer
Dionne F, Aminkeng F, Bhavsar AP, Groeneweg G, Smith A, Visscher H, Rassekh SR, Ross C, Carleton B
DOI: 10.1002/pbc.26887
PubMed: 29271558
03/2018

Assessment of hair cortisol as a potential biomarker for possible adrenal suppression due to inhaled corticosteroid use in children with asthma: A retrospective observational study.
Clinical biochemistry
Smy L, Shaw K, Amstutz U, Staub M, Chaudhry S, Smith A, Carleton B, Koren G
DOI: 10.1016/j.clinbiochem.2018.04.006
PubMed: 29673814
04/2018

Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
PloS one
Bhavsar AP, Gunaretnam EP, Li Y, Hasbullah JS, Carleton BC, Ross CJ
DOI: 10.1371/journal.pone.0175711
PubMed: 28406961
2017

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
JAMA oncology
Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Carleton BC
DOI: 10.1001/jamaoncol.2017.0502
PubMed: 28448657
11/2017

Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity.
Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC, CPNDS Clinical Practice Recommendations Group
DOI: 10.1111/bcp.13008
PubMed: 27197003
05/2016

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ, Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1038/ng.3374
PubMed: 26237429
09/2015

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC, CPNDS clinical recommendation group
DOI: 10.1111/epi.12564
PubMed: 24597466
04/2014

Economic impact of a genetic test for cisplatin-induced ototoxicity.
Dionne F, Mitton C, Rassekh R, Brooks B, Ross C, Hayden M, Carleton B
DOI: 10.1038/tpj.2011.15
PubMed: 21502965
06/2012

The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR, CPNDS Consortium
DOI: 10.1089/thy.2010.1642
PubMed: 20578893
07/2010

Risk of Anterior Segment Complications Associated With the Live Herpes Zoster Vaccine: Evidence From a Health-Claim Database.
Cornea
Liu RT, Yeung SN, Carleton B, Etminan M
DOI: 10.1097/ico.0000000000001595
PubMed: 29601366
03/2018

Association of Post-operative Topical Prostaglandin Analog or Beta-blocker Use and Incidence of Pseudophakic Cystoid Macular Edema.
Journal of glaucoma
Wendel C, Zakrzewski H, Carleton B, Etminan M, Mikelberg FS
DOI: 10.1097/ijg.0000000000000929
PubMed: 29505438
03/2018

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Clinical pharmacology and therapeutics
Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL, Mushiroda T, Pirmohamed M
DOI: 10.1002/cpt.1004
PubMed: 29392710
02/2018

Risk of hair loss with different antidepressants: a comparative retrospective cohort study.
International clinical psychopharmacology
Etminan M, Sodhi M, Procyshyn RM, Guo M, Carleton BC
DOI: 10.1097/yic.0000000000000191
PubMed: 28763345
01/2018

Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.
Neurology
McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S, Becker F, Rau S, Avbersek A, Heggeli K, Leu C, Cavalleri GL
DOI: 10.1212/wnl.0000000000004853
PubMed: 29288229
01/2018

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.
The journal of allergy and clinical immunology. In practice
White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Phillips EJ
DOI: 10.1016/j.jaip.2017.11.023
PubMed: 29310768
2018

Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.
PM & R : the journal of injury, function, and rehabilitation
McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, Leeder JS
DOI: 10.1016/j.pmrj.2017.08.441
PubMed: 28867665
09/2017

Dentists’ Prescribing of Analgesics for Children in British Columbia, Canada
Journal (Canadian Dental Association)
Etminan M, Nouri MR, Sodhi M, Carleton BC
PubMed: 29360020
08/2017

Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study.
Neurology
Sodhi M, Sheldon CA, Carleton B, Etminan M
DOI: 10.1212/wnl.0000000000004247
PubMed: 28754842
08/2017

Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Cheng JZ, Sodhi M, Etminan M, Carleton BC
DOI: 10.1093/cid/cix362
PubMed: 28444196
08/2017

Physician and parent barriers to the use of oral corticosteroids for the prevention of paediatric URTI-induced acute asthma exacerbations at home.
Paediatrics & child health
Smith N, Smith A, Wang A, Shaw K, Groeneweg G, Goldman RD, Wilkinson B, Jimenez R, Mwai L, Carleton B
DOI: 10.1093/pch/pxx047
PubMed: 29479212
07/2017

Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium.
Pharmacogenomics
Farzan N, Vijverberg SJ, Andiappan AK, Arianto L, Berce V, Blanca-López N, Bisgaard H, Bønnelykke K, Burchard EG, Campo P, Canino G, Carleton B, Maitland-van der Zee AH
DOI: 10.2217/pgs-2017-0035
PubMed: 28639505
07/2017

Improved strength on 5-hydroxytryptophan and carbidopa in spinal cord atrophy.
Journal of the neurological sciences
Horvath GA, Meisner L, Selby K, Stowe R, Carleton B
DOI: 10.1016/j.jns.2017.04.047
PubMed: 28566180
07/2017

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
BMJ open
Kowalec K, Kingwell E, Carruthers R, Marrie RA, Bernatsky S, Traboulsee A, Ross CJD, Carleton B, Tremlett H
DOI: 10.1136/bmjopen-2017-016276
PubMed: 28576902
06/2017

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.
British journal of clinical pharmacology
Aminkeng F, Ross CJD, Rassekh SR, Rieder MJ, Bhavsar AP, Sanatani S, Bernstein D, Hayden MR, Amstutz U, Carleton BC
DOI: 10.1111/bcp.13218
PubMed: 28317142
05/2017

Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery.
JAMA ophthalmology
Eadie BD, Etminan M, Carleton BC, Maberley DA, Mikelberg FS
DOI: 10.1001/jamaophthalmol.2017.0059
PubMed: 28301639
04/2017

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.
Canadian journal of kidney health and disease
McMahon KR, Rod Rassekh S, Schultz KR, Pinsk M, Blydt-Hansen T, Mammen C, Tsuyuki RT, Devarajan P, Cuvelier GD, Mitchell LG, Baruchel S, Palijan A, Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group
DOI: 10.1177/2054358117690338
PubMed: 28270931
2017

Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.
Etminan M, Sodhi M, Samii A, Procyshyn RM, Guo M, Carleton BC
PubMed: 27930495
12/2016

The global spectrum of protein-coding pharmacogenomic diversity.
Wright GE, Carleton B, Hayden MR, Ross CJ
DOI: 10.1038/tpj.2016.77
PubMed: 27779249
10/2016

Risk of Extrapyramidal Adverse Events With Aripiprazole.
Etminan M, Procyshyn RM, Samii A, Carleton BC
DOI: 10.1097/jcp.0000000000000543
PubMed: 27580493
10/2016

Oral morphine dosing predictions based on single dose in healthy children undergoing surgery.
Dawes JM, Cooke EM, Hannam JA, Brand KA, Winton P, Jimenez-Mendez R, Aleksa K, Lauder GR, Carleton BC, Koren G, Rieder MJ, Anderson BJ, Montgomery CJ
DOI: 10.1111/pan.13020
PubMed: 27779356
10/2016

Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study.
Etminan M, Westerberg BD, Kozak FK, Guo MY, Carleton BC
PubMed: 27497265
08/2016

Asthma in British Columbia: Are We Finally Breathing Easier? A population based study of the burden of disease Over 14 Years.
Bardal S, Smith A, Luo HA, Zhang T, Groeneweg G, Jimenez Mendez R, Goldman R, Carleton B
PubMed: 27414432
07/2016

An in silico framework for integrating epidemiologic and genetic evidence with health care applications: ventilation-related pneumothorax as a case illustration.
Torosyan Y, Hu Y, Hoffman S, Luo Q, Carleton B, Marinac-Dabic D
DOI: 10.1093/jamia/ocw031
PubMed: 27107435
07/2016

Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration.
Etminan M, Maberley DA, Babiuk DW, Carleton BC
DOI: 10.1016/j.ajo.2016.03.026
PubMed: 27093892
06/2016

Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.
Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH
PubMed: 27142473
05/2016

Clinical Practice Recommendations For The Management And Prevention Of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
Lee JW, Pussegoda K, Rassekh RS, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC, CPNDS clinical recommendations group
PubMed: 26960170
03/2016

Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration.
Etminan M, Maberley DA, Babiuk DW, Carleton BC
DOI: 10.1016/j.ajo.2015.11.030
PubMed: 26701272
03/2016

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics.
Chan SL, Samaranayake N, Ross CJ, Toh MT, Carleton B, Hayden MR, Teo YY, Dissanayake VH, Brunham LR
DOI: 10.1097/FPC.0000000000000182
PubMed: 26444257
01/2016

Hair cortisol as a hypothalamic-pituitary-adrenal axis biomarker in pregnant women with asthma: a retrospective observational study.
Smy L, Shaw K, Amstutz U, Smith A, Berger H, Carleton B, Koren G
DOI: 10.1186/s12884-016-0962-4
PubMed: 27440139
2016

Risperidone and Risk of Gynecomastia in Young Men.
Etminan M, Carleton B, Brophy JM
DOI: 10.1089/cap.2015.0024
PubMed: 26287371
11/2015

A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N, Jimenez-Mendez R, Cooke E, Montgomery CJ, Dawes J, Rieder MJ, Aleksa K, Koren G, Jacobo-Cabral CO, Gonzalez-Ramirez R, Castañeda-Hernandez G, Carleton BC
DOI: 10.1007/s40262-015-0256-4
PubMed: 25773480
10/2015

The pharmacogenetics of codeine pain relief in the postpartum period.
Baber M, Chaudhry S, Kelly L, Ross C, Carleton B, Berger H, Koren G
DOI: 10.1038/tpj.2015.3
PubMed: 25752520
10/2015

Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
Jiménez-Triana CA, Castelán-Martínez OD, Rivas-Ruiz R, Jiménez-Méndez R, Medina A, Clark P, Rassekh R, Castañeda-Hernández G, Carleton B, Medeiros M, Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1097/MD.0000000000001413
PubMed: 26313789
08/2015

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.
Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, Ito S, Ross C, Carleton BC, CPNDS Clinical Recommendation Group
DOI: 10.1097/FTD.0000000000000192
PubMed: 26186657
08/2015

Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children.
Smy L, Shaw K, Smith A, Russell E, Van Uum S, Rieder M, Carleton B, Koren G
DOI: 10.1038/pr.2015.60
PubMed: 25790275
07/2015

Association between regulatory advisories and codeine prescribing to postpartum women.
Smolina K, Weymann D, Morgan S, Ross C, Carleton B
DOI: 10.1001/jama.2015.3642
PubMed: 25965237
05/2015

Post-renal transplant erythrocytosis: a case report.
Almonte M, Velásquez-Jones L, Valverde S, Carleton B, Medeiros M
DOI: 10.1111/petr.12406
PubMed: 25418869
02/2015

Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study.
Etminan M, Skeldon SC, Goldenberg SL, Carleton B, Brophy JM
DOI: 10.1002/phar.1534
PubMed: 25582846
01/2015

Use of pharmacogenomics in pediatric renal transplant recipients.
Medeiros M, Castañeda-Hernández G, Ross CJ, Carleton BC
DOI: 10.3389/fgene.2015.00041
PubMed: 25741362
2015

Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research.
Syme R, Carleton B, Leyens L, Richer E
DOI: 10.1159/000441560
PubMed: 26565702
2015

Genetic determinants of cocaine-associated agranulocytosis.
Buxton JA, Omura J, Kuo M, Ross C, Tzemis D, Purssell R, Gardy J, Carleton B
DOI: 10.1186/s13104-015-1219-4
PubMed: 26070312
2015

New Ways of Detecting ADRs in Neonates and Children.
Jimenez R, Smith A, Carleton B
PubMed: 26323415
2015

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ, CPNDS consortium
DOI: 10.2217/pgs.15.61
PubMed: 26230641
2015

Pharmacogenomic diversity in Singaporean populations and Europeans.
Brunham LR, Chan SL, Li R, Aminkeng F, Liu X, Saw WY, Ong RT, Pillai EN, Carleton BC, Toh D, Tan SH, Koo SH, Lee EJ, Chia KS, Ross CJ, Hayden MR, Sung C, Teo YY
DOI: 10.1038/tpj.2014.22
PubMed: 24861855
12/2014

Emergency department visits for children with acute asthma: discharge instructions, parental plans, and follow-through of care--a prospective study.
Camp PG, Norton SP, Goldman RD, Shajari S, Smith MA, Heathcote S, Carleton B
PubMed: 25358278
11/2014

Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell TL, Wadelius M, Carleton B, Tremlett H
DOI: 10.1517/14740338.2014.947958
PubMed: 25134421
10/2014

Risperidone use and risk for gynecomastia in men.
Etminan M, Heran B, Carleton B, Brophy JM
DOI: 10.1097/JCP.0000000000000182
PubMed: 25006814
10/2014

Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR
DOI: 10.1038/clpt.2014.92
PubMed: 25141953
09/2014

Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD, Jiménez-Méndez R, Rodríguez-Islas F, Fierro-Evans M, Vázquez-Gómez BE, Medina-Sansón A, Clark P, Carleton B, Ross C, Hildebrand C, Castañeda-Hernández G, Rivas-Ruiz R
DOI: 10.1016/j.ijporl.2014.06.007
PubMed: 25037447
09/2014

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR
DOI: 10.1038/clpt.2014.90
PubMed: 24755913
08/2014

The emerging era of pharmacogenomics: current successes, future potential, and challenges.
Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ
DOI: 10.1111/cge.12392
PubMed: 24684508
07/2014

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC
DOI: 10.1002/pbc.24932
PubMed: 24474498
06/2014

Codeine-related deaths: The role of pharmacogenetics and drug interactions.
Lam J, Woodall KL, Solbeck P, Ross CJ, Carleton BC, Hayden MR, Koren G, Madadi P
DOI: 10.1016/j.forsciint.2014.03.018
PubMed: 24747667
06/2014

Development of a broad-based ADME panel for use in pharmacogenomic studies.
Brown AM, Renaud Y, Ross C, Hansen M, Mongrain I, Valois D, Carleton BC, Hayden MR, Dubé MP, Tardif JC, Phillips MS
DOI: 10.2217/pgs.14.81
PubMed: 25141894
06/2014

Rising antipsychotic prescriptions for children and youth: cross-sectoral solutions for a multimodal problem.
Di Pietro N, Illes J, Canadian Working Group on Antipsychotic Medications and Children
DOI: 10.1503/cmaj.131604
PubMed: 24664655
06/2014

Public perceptions of pharmacogenetics.
Zhang SC, Bruce C, Hayden M, Rieder MJ
DOI: 10.1542/peds.2013-1416
PubMed: 24777223
05/2014

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.
Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR, Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1038/tpj.2013.13
PubMed: 23588107
04/2014

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR
DOI: 10.1038/clpt.2013.219
PubMed: 24193170
03/2014

Exome sequencing pilot study in children with carbamazepine-induced serious skin reactions.
Amstutz U, Shyr C, Shear NH, Rieder MJ, Wasserman WW, Ross CJ, Carleton BC
DOI: 10.1186/2045-7022-4-S3-P119
2014

Pharmacogenomics and adverse drug reactions in children.
Rieder MJ, Carleton B
DOI: 10.3389/fgene.2014.00078
PubMed: 24795743
2014

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, CPNDS Consortium
DOI: 10.1002/pbc.24505
PubMed: 23441093
08/2013

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Zada YF, Dubé MP, Carleton BC, Hayden MR, CPNDS Consortium
DOI: 10.1038/clpt.2013.80
PubMed: 23588304
08/2013

Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers.
Lam J, Kelly L, Matok I, Ross CJ, Carleton BC, Hayden MR, Madadi P, Koren G
DOI: 10.1097/FTD.0b013e318288f158
PubMed: 23783165
08/2013

HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.
Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC, CPNDS Consortium
DOI: 10.1038/clpt.2013.55
PubMed: 23588310
07/2013

The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis.
Kowalec K, Carleton B, Tremlett H
DOI: 10.1016/j.msard.2012.11.003
PubMed: 25877724
07/2013

High use of health services in patients with suboptimal asthma drug regimens: a population-based assessment in British Columbia, Canada.
Zhang T, Smith MA, Camp PG, Carleton BC
DOI: 10.1002/pds.3444
PubMed: 23559540
07/2013

Cancer pharmacogenomics in children: research initiatives and progress to date.
Rassekh SR, Ross CJ, Carleton BC, Hayden MR
DOI: 10.1007/s40272-013-0021-9
PubMed: 23529868
04/2013

Prescription drug dispensing profiles for one million children: a population-based analysis.
Zhang T, Smith MA, Camp PG, Shajari S, MacLeod SM, Carleton BC
DOI: 10.1007/s00228-012-1343-1
PubMed: 22791273
03/2013

Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient.
Kowalec K, Yoshida EM, Traboulsee A, Carleton B, Tremlett H
DOI: 10.1016/j.msard.2012.07.004
PubMed: 25877455
01/2013

Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.
Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC, CPNDS Clinical Recommendations Group
PubMed: 24214521
2013

A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk.
Kelly LE, Chaudhry SA, Rieder MJ, 't Jong G, Moretti ME, Lausman A, Ross C, Berger H, Carleton B, Hayden MR, Madadi P, Koren G
DOI: 10.1371/journal.pone.0070073
PubMed: 23922910
2013

Physician variability in treating pain and irritability of unknown origin in children with severe neurological impairment.
Siden HB, Carleton BC, Oberlander TF
PubMed: 23885348
2013

Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT.
Shaw K, Amstutz U, Castro-Pastrana L, Loo TT, Ross CJ, Ito S, Reider MJ, Maher M, Macleod S, Koren G, Hayden MR, Carleton BC
PubMed: 23824325
2013

Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?
Madadi P, Sistonen J, Silverman G, Gladdy R, Ross CJ, Carleton BC, Carvalho JC, Hayden MR, Koren G
PubMed: 23748253
2013

The use of long-acting ß2- agonists as monotherapy in children and adults.
Camp PG, Zhang T, Smith MA, Carleton BC
PubMed: 23392793
2013

Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study.
Khetani JD, Madadi P, Sommer DD, Reddy D, Sistonen J, Ross CJ, Carleton BC, Hayden MR, Koren G
DOI: 10.1007/BF03262421
PubMed: 23013460
12/2012

Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: the devil is in the details.
Lam J, Matlow JN, Ross CJ, Hayden MR, Carleton BC, Madadi P
DOI: 10.1097/FTD.0b013e31825da19f
PubMed: 22777151
08/2012

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR
DOI: 10.1038/tpj.2010.92
PubMed: 21243006
06/2012

More codeine fatalities after tonsillectomy in North American children.
Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G
DOI: 10.1542/peds.2011-2538
PubMed: 22492761
05/2012

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR, Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1200/JCO.2010.34.3467
PubMed: 21900104
05/2012

Suspected opioid overdose case resolved by CYP2D6 genotyping.
Shaw KD, Amstutz U, Jimenez-Mendez R, Ross CJ, Carleton BC
DOI: 10.1097/FTD.0b013e31824a1e21
PubMed: 22406651
04/2012

Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.
Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer ML, Nauta M, Carleton BC, Koren G, Hayden MR
DOI: 10.1038/clpt.2011.280
PubMed: 22398969
04/2012

Fifty years of pediatric asthma in developed countries: how reliable are the basic data sources?
Chawla J, Seear M, Zhang T, Smith A, Carleton B
DOI: 10.1002/ppul.21537
PubMed: 21905263
03/2012

Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia.
Lam J, Kelly L, Ciszkowski C, Landsmeer ML, Nauta M, Carleton BC, Hayden MR, Madadi P, Koren G
DOI: 10.1016/j.jpeds.2011.06.050
PubMed: 21880331
01/2012

Beta-blocker use and COPD mortality: a systematic review and meta-analysis.
Etminan M, Jafari S, Carleton B, FitzGerald JM
DOI: 10.1186/1471-2466-12-48
PubMed: 22947076
2012

Using pharmacogenetics to understand adverse drug reactions in children.
Shaw K, Amstutz U, Carleton BC
PubMed: 23115490
11/2011

Diagnostic testing for vaccinomics: is the regulatory approval framework adequate? A comparison of Canada, the United States, and Europe.
Joly Y, Koutrikas G, Ramos-Paque E, Zawati M, Gardy J, Hayden MR, Carleton BC
DOI: 10.1089/omi.2010.0135
PubMed: 21728814
09/2011

Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC
DOI: 10.1097/FJC.0b013e3182163b82
PubMed: 21386709
09/2011

Technology enabled knowledge exchange: development of a conceptual framework.
Househ M, Kushniruk A, Cloutier-Fisher D, Carleton B
DOI: 10.1007/s10916-009-9408-0
PubMed: 20703520
08/2011

CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, Hayden MR, Koren G
DOI: 10.1097/FTD.0b013e3182272b10
PubMed: 21743374
08/2011

A literature review on distance knowledge exchange in healthcare groups: what can we learn from the ICT literature?
Househ MS, Kushniruk A, Carleton B, Cloutier-Fisher D
DOI: 10.1007/s10916-009-9401-7
PubMed: 20703525
08/2011

Phenotype standardization for immune-mediated drug-induced skin injury.
Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L, Carleton B, Papaluca-Amati M, Demoly P, Shear NH
DOI: 10.1038/clpt.2011.79
PubMed: 21562486
06/2011

Pharmacogenetic testing: time for clinical practice guidelines.
Amstutz U, Carleton BC
DOI: 10.1038/clpt.2011.18
PubMed: 21508939
06/2011

The use of conferencing technologies to support drug policy group knowledge exchange processes: an action case approach.
Househ MS, Kushniruk A, Maclure M, Carleton B, Cloutier-Fisher D
DOI: 10.1016/j.ijmedinf.2010.10.020
PubMed: 21167772
04/2011

Sildenafil citrate therapy for severe early-onset intrauterine growth restriction.
von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN, Research into Advanced Fetal Diagnosis and Therapy (RAFT) Group
DOI: 10.1111/j.1471-0528.2010.02879.x
PubMed: 21392225
04/2011

A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ
PubMed: 21467603
2011

Pharmacogenomics of serious adverse drug reactions in pediatric oncology.
Ross CJ, Visscher H, Rassekh SR, Castro-Pastrana LI, Shereck E, Carleton B, Hayden MR
PubMed: 21467604
2011

Strengths and weaknesses of using conferencing technologies to support drug policy knowledge exchange.
Househ MS, Kushniruk AW, Macclure M, Carleton B, Cloutier-Fisher D
PubMed: 21335744
2011

Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge.
Castro-Pastrana LI, Carleton BC
PubMed: 21467599
2011

The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study.
Madadi P, Joly Y, Avard D, Chitayat DC, Smith MA, D Ross CJ, Carleton BC, Hayden MR, Koren G
PubMed: 21467605
2011

Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS).
Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton B
PubMed: 21467602
2011

Regulatory approval for new pharmacogenomic tests: a comparative overview.
Joly Y, Koutrikas G, Tassé AM, Issa A, Carleton B, Hayden M, Rieder MJ, Ramos-Paque E, Avard D
PubMed: 24505844
2011

Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits.
Madadi P, Joly Y, Avard D, Chitayat DC, Smith MA, Ross CJ, Carleton BC, Hayden MR, Koren G
DOI: 10.1038/clpt.2010.125
PubMed: 20739920
12/2010

Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.
Carleton B
DOI: 10.1038/clpt.2010.242
PubMed: 21081946
12/2010

Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.
Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G
DOI: 10.1542/peds.2009-1907
PubMed: 20837591
10/2010

Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Loo TT, Ross CJ, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC
DOI: 10.2217/pgs.10.111
PubMed: 20860467
09/2010

Palivizumab for the prevention of respiratory syncytial virus infection.
Rogovik AL, Carleton B, Solimano A, Goldman RD
PubMed: 20705882
08/2010

Gene-based warfaring dosing.
Carleton B
DOI: 10.1097/FTD.0b013e3181e1a665
PubMed: 20498559
06/2010

Predictive genotype.
Ito S, Carleton BC
DOI: 10.1503/cmaj.110-2061
PubMed: 20479057
05/2010

The comorbidity burden of the treated asthma patient population in British Columbia.
Prosser R, Carleton B, Smith A
PubMed: 20302685
03/2010

Cases: Cocaine adulterant linked to neutropenia.
Wiens MO, Son WK, Ross C, Hayden M, Carleton B
DOI: 10.1503/cmaj.090286
PubMed: 19969562
01/2010

Direct health care costs associated with asthma in British Columbia.
Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC, Sullivan S, Fitzgerald JM
PubMed: 20422063
2010

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR, CPNDS Consortium
DOI: 10.1038/ng.478
PubMed: 19898482
12/2009

Application of principal component analysis to pharmacogenomic studies in Canada.
Visscher H, Ross CJ, Dubé MP, Brown AM, Phillips MS, Carleton BC, Hayden MR
DOI: 10.1038/tpj.2009.36
PubMed: 19652663
12/2009

The added burden of comorbidity in patients with asthma.
Zhang T, Carleton BC, Prosser RJ, Smith AM
DOI: 10.3109/02770900903350473
PubMed: 19995140
12/2009

Use of oseltamivir in children.
Jamieson B, Jain R, Carleton B, Goldman RD
PubMed: 20008597
12/2009

Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, Phillips M, Hayden M
DOI: 10.1002/pds.1772
PubMed: 19507171
08/2009

Thiazolidinediones and fractures in men and women.
Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM
DOI: 10.1001/archinternmed.2009.214
PubMed: 19667303
08/2009

Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.
Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G
DOI: 10.1038/clpt.2008.157
PubMed: 18719619
01/2009

Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safety.
Wong E, Carleton BC, Wright DF, Smith MA, Verbeek L, Hildebrand CA, Stannard P, Vaillancourt R, Elliot-Miller P, Ross CJ, Hayden MR
PubMed: 19380938
2009

A case study examining the impacts of conferencing technologies in distributed healthcare groups.
Househ M, Kushniruk A, Maclure M, Carleton B, Cloutier-Fisher D
PubMed: 20057239
2009

Drug formulary decision-making in two regional health authorities in British Columbia, Canada.
Armstrong K, Mitton C, Carleton B, Shoveller J
DOI: 10.1016/j.healthpol.2008.04.006
PubMed: 18508151
12/2008

Statin use and the risk of Parkinson disease: a nested case control study.
Samii A, Carleton BC, Etminan M
DOI: 10.1016/j.jocn.2008.01.016
PubMed: 18823780
11/2008

Camouflaged sampling and contacting of people from administrative databases: reaching target patients without knowing who they are.
Maclure M, Warren L, Willison D, Cassels A, Carleton B
DOI: 10.1002/pds.1623
PubMed: 18615549
08/2008

Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study.
Etminan M, Carleton BC, Samii A
DOI: 10.1016/j.jocn.2007.02.095
PubMed: 18343119
05/2008

Identifying persons with treated asthma using administrative data via latent class modelling.
Prosser RJ, Carleton BC, Smith MA
DOI: 10.1111/j.1475-6773.2007.00775.x
PubMed: 18370976
04/2008

Medication errors: neonates, infants and children are the most vulnerable!
Poole RL, Carleton BC
DOI: 10.5863/1551-6776-13.2.65
PubMed: 23055866
04/2008

Trends in psychostimulant and antidepressant use by children in 2 Canadian provinces.
Mitchell B, Carleton B, Smith A, Prosser R, Brownell M, Kozyrskyj A
PubMed: 18441661
03/2008

Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
Maclure M, Carleton B, Schneeweiss S
DOI: 10.1097/MLR.0b013e318068932a
PubMed: 17909382
10/2007

Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children.
Ross CJ, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR
DOI: 10.1196/annals.1423.020
PubMed: 17911433
09/2007

Effect of a clinical pathway on the hospitalisation rates of children with asthma: a prospective study.
Norton SP, Pusic MV, Taha F, Heathcote S, Carleton BC
DOI: 10.1136/adc.2006.097287
PubMed: 16905562
01/2007

Pharmacogenomics and its implications for autoimmune disease.
Ross CJ, Katzov H, Carleton B, Hayden MR
DOI: 10.1016/j.jaut.2007.02.008
PubMed: 17418528
2007

Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC, Smith MA, Gelin MN, Heathcote SC
PubMed: 17297195
2007

Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia.
Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, Côté AM, von Dadelszen P
DOI: 10.1016/j.ajog.2004.11.059
PubMed: 16021073
07/2005

Formulas containing live probiotic bacteria.
Falk J, Carleton B, Gerber P
PubMed: 15321825
09/2004

Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials.
Etminan M, Carleton B, Delaney JA, Padwal R
DOI: 10.1592/phco.24.4.338.33181
PubMed: 15040646
03/2004

Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.
Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J
DOI: 10.1136/bmj.38020.698194.F6
PubMed: 14982865
03/2004

Quantifying adverse drug events : are systematic reviews the answer?
Etminan M, Carleton B, Rochon PA
DOI: 10.2165/00002018-200427110-00001
PubMed: 15350149
2004

Recognizing idiosyncratic adverse drug reactions in children: A practice imperative.
Carleton B, Primmett D
PubMed: 20084233
04/2001

From professional advocacy to patient advocacy: a gambit for pharmacists.
Carleton BC
PubMed: 11216105
2001

Effects and ethics of sanctions on childhood immunization rates.
Maclure M, Carleton B, Schneeweiss S
DOI: 10.1001/jama.284.16.2056
PubMed: 11042749
10/2000

Evidence-based pharmacotherapy: review of basic concepts and applications in clinical practice.
Etminan M, Wright JM, Carleton BC
DOI: 10.1345/aph.17333
PubMed: 9825086
11/1998

Simple approach to dosage adjustment in patients with renal impairment.
McCormack JP, Cooper J, Carleton B
PubMed: 9359960
11/1997

A simpler approach to pharmacokinetic dosage adjustments.
McCormack JP, Carleton B
PubMed: 9399625
1997

Drug and poison information resources on the Internet, Part 2: Identification and evaluation.
Marra CA, Carleton BC, Lynd LD, Marra F, McDougal AR, Chow D, McKerrow R
PubMed: 8888076
1996

Overview of health-related quality-of-life measures for pediatric patients: application in the assessment of pharmacotherapeutic and pharmacoeconomic outcomes.
Marra CA, Levine M, McKerrow R, Carleton BC
PubMed: 8888083
1996

Drug and poison information resources on the Internet, Part 1: An introduction.
Marra CA, Lynd LD, McKerrow R, Carleton BC
PubMed: 8840360
1996

Comment: cost of rhDNase in cystic fibrosis.
Marra CA, Carleton BC, Basmadjian D, Levine M, McKerrow R
PubMed: 8845550
10/1995

Spurious rise in total carbon dioxide and chloride with negative anion gap after cystogram.
Abdel-Wareth LO, Lirenman DS, Halstead AC, McLellan D, Carleton BC
DOI: 10.1007/BF02254207
PubMed: 7632530
06/1995

Effects of three immunosuppressive drug protocols on cadaver renal transplantation costs after 4 years of therapy.
Canafax DM, Carleton BC, Matas AJ, Payne WD, Dunn DL, Sutherland DE, Najarian JS
PubMed: 8442239
02/1993

Method for evaluating drip-rate accuracy of intravenous flow-regulating devices.
Carleton BC, Cipolle RJ, Larson SD, Canafax DM
PubMed: 1746576
11/1991

Reversed-phase high-performance liquid chromatographic approach to determine total lymphocyte concentrations of 6-thioguanine, methylmercaptopurine and methylthioguanine in humans.
Erdmann GR, Steury JC, Carleton BC, Stafford RJ, Bostrom BC, Canafax DM
PubMed: 1810943
11/1991

Interaction between cyclosporine and fluconazole in renal allograft recipients.
Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ
PubMed: 2031258
05/1991

Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study.
Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ
PubMed: 1989149
02/1991

Research

Genomic and Outcomes Databank for Pharmacogenomic and Implementation Studies (GO PGx)
This Genome Canada project will reduce adverse drug reactions (ADRs) by developing genomic-based precision health strategies and technologies for the most common and severe ADRs in pediatric oncology and facilitate the implementation of pharmacogenomics into clinical practice. This will be realized through four parallel and complementary research activities that will result in genomic-based precision health deliverables for unique end-users:
1. Establish an ADR database of linked clinical and genomic data to discover and validate biomarkers of five severe ADRs associated with cancer therapy drugs in children.
2. Knowledge translation (KT) to facilitate the use of pharmacogenomics in pediatric oncology through the development of clinical practice guidelines and an educational program.
3. Implement ADR-predictive pharmacogenomics tests at 10 pediatric oncology centres across Canada
4. Exploration of how pharmacogenomics testing in pediatric oncology impacts, and is impacted by patients, families, clinicians, and the Canadian healthcare system (GE3LS).

Integrating pediatric pharmacogenomic testing into the Canadian health care system
This project is focused on developing pharmacogenomic tests to predict the risk of experiencing an adverse drug reaction (ADR) in pediatric patients, and strives to bridge the gap between the rigorous science of pharmacogenomics and its integration into health care by providing a tool for the clinical uptake of rigorously derived pharmacogenomic information. To bridge this gap, we have identified actionable pharmacogenomic biomarkers for the most frequently prescribed medication classes and associated ADRs in children: antibiotics, analgesics, and mental health medications. These pharmacogenomic biomarkers all have a compelling rationale for inclusion and were based upon recommendations from FDA and/or Health Canada, Clinical Practice Guidelines, or discovery and replication of research findings in at least three independent populations. Using these robust genomic findings, we will develop three pharmacogenomic panels that possess high analytical validity as well as clinical utility. This product will therefore make the proven benefits of pharmacogenomics accessible to all pediatric patients and their clinicians and pharmacists in Canada. The availability of such tests would provide huge advantages to the thousands of children receiving these frequently prescribed medications every year and will significantly decrease the prevalence of severe and debilitating ADRs related to the most commonly prescribed medications in children.

Grants

DSEN-SEARCH: active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare – CIHR (2011-2014)

The Canadian Pharmacogenomics Network for Drug Safety - Canada Foundation for Innovation/ Canadian Institutes for Health Research (2008-2013)

DSEN-PREVENT: Pharmacogenomics of Adverse Reactions EVEnts Nation-wide Team – CIHR (2011-2014)

Pharmacogenomics of Warfarin Safety and Effectiveness in Children – CIHR (2012-2013)

Honours & Awards

2011 Canadian Society of Pharmacology and Therapeutics (CSPT) Senior Investigator Award

2009 Award for Clinical Research, CIHR Institute of Human Development, Child and Youth Health (IHDCYH) for the Best Research Poster: Effectiveness of inhaled corticosteroids in preventing morbidity and mortality in individuals with chronic obstructive pulmonary disease and the impact of coexisting asthma. Presented at the IHDCYH Scientific Forum, Winnipeg Manitoba, May 2009.

2008 Awards for Clinical Research, Canadian Association of Paediatric Health Centres (CAPHC) and McMaster University Child Health Research Institute for the Best Research Poster: Genotypic Approaches to Therapy in Children: A National ADR Surveillance Network to Study and Prevent Severe Adverse Drug Reactions in Children. Presented at the CAPHC Annual meeting, Edmonton Alberta, October 2008.

Research Group Members

Zazuli Zulfan
Tina-Marie Dryden
Britt Drogemoller
Gabriella Groeneweg, Program Manager
Galen Wright
Jessica Trueman, Research Assistant
Reo Tanoshima
Tessa Bendyshe-Walton
Erandika Prasadani Gunaretnam, Research Technician
Nicole McGoldrick
Miki Tanoshima
Kathy Wan-Chun Chang
Tom Ouellette
Victor Wong, Undergraduate Student
Angeleet Dhanda, Undergraduate Student
Maya Brassard
Tan Toan Le
Catrina Loucks
Kevin Yan
Jennifer Lin
Agnieszka Biala
Ellen Kim, Research Staff